| Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2017: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2016: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2015: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Outline of Final Research Achievements |
In this study, we have evaluated HVEM expression in hepatocellular carcinoma and colorectal cancer. As a result, tumor HVEM expression had a significant prognostic value. Furthermore, HVEM expression was inversely correlated with tumor-infiltrating T cells, suggesting its important role in tumor immunity.
In addition, we have evaluated CD155 and Nectin family in human pancreatic cancer. We found such molecules had significant prognostic value and played an important role in pancreatic cancer. Therefore, targeting T cell negative pathways including HVEM, CD155, and Nectin family may hold significant promise for future clinical application in cancer immunotherapy.
|
